Galera Therapeutics
Presence
Galera Therapeutics is a company listed under the stock ticker GRTX (US).
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Galera Therapeutics
- Mel Sorensen, Director, President and Chief Executive Officer
- Linda West, Director
- Mike Powell, Chairman of the Board
Popular executive movements at Galera Therapeutics
- Mark Bachleda, Chief Commercial Officer, has left the company (posted on August 18 2023).
Create your alert
to follow the executive moves at Galera Therapeutics.
Biotechnology
Galera Therapeutics has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Galera Therapeutics
- Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer | Galera Therapeutics
- Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 | Galera Therapeutics
- Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | Galera Therapeutics
- Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer | Galera Thera
- Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates | Galera Therapeutics
- News Releases | Galera Therapeutics
- Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference | Galera Therapeutics
- Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer | Galera Therapeutics
- Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin | Galera Therapeutics
- Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease | Galera Therapeutics
- View more press releases Close
Social media about Galera Therapeutics
- Galera Therapeutics on Wikipedia, Google News & Yahoo Finance
- Galera Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Mel Sorensen 
Call Galera Therapeutics at +1 610...
